StocksFundsScreenerSectorsWatchlists
RGEN

RGEN - Repligen Corp Stock Price, Fair Value and News

184.32USD-0.43 (-0.23%)Delayed as of 28 Mar 2024, 10:59 am ET

Market Summary

RGEN
USD184.32-0.43
Delayedas of 28 Mar 2024, 10:59 am
-0.23%

RGEN Alerts

  • 4 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

RGEN Stock Price

View Fullscreen

RGEN RSI Chart

RGEN Valuation

Market Cap

10.3B

Price/Earnings (Trailing)

247.82

Price/Sales (Trailing)

16.13

EV/EBITDA

75

Price/Free Cashflow

132.62

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

10.04%

Return on Equity

2.11%

Return on Assets

1.47%

Free Cashflow Yield

0.75%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

638.8M

Rev. Growth (Yr)

-16.61%

Rev. Growth (Qtr)

10.31%

RGEN Earnings

Earnings (TTM)

41.6M

Earnings Growth (Yr)

-152.31%

Earnings Growth (Qtr)

-240.26%

Breaking Down RGEN Revenue

52 Week Range

134.64184.54
(Low)(High)

Last 7 days

4.3%

Last 30 days

-5.0%

Last 90 days

8.4%

Trailing 12 Months

14.2%

How does RGEN drawdown profile look like?

RGEN Financial Health

Current Ratio

7.02

Debt/Equity

0.26

Debt/Cashflow

0.22

RGEN Investor Care

Shares Dilution (1Y)

0.38%

Diluted EPS (TTM)

0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023777.8M729.3M669.8M638.8M
2022734.1M778.8M801.3M801.5M
2021433.0M508.5M592.7M670.5M
2020285.7M302.5M327.1M366.3M
2019209.8M232.8M252.7M270.2M
2018155.5M170.8M183.7M194.0M
2017110.0M113.3M125.2M141.2M
201687.8M95.5M100.4M104.5M
201566.9M72.8M77.5M83.5M
201466.0M64.1M60.4M60.4M
201365.9M67.9M71.6M68.2M
201236.3M44.1M50.6M62.3M
201127.3M27.9M29.3M29.4M
201021.0M22.6M24.1M25.7M

Tracking the Latest Insider Buys and Sells of Repligen Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
pax margaret
acquired
-
-
92.00
-
Mar 18, 2024
hunt anthony
gifted
-
-
-2,000
chief executive officer
Mar 11, 2024
kuriyel ralf
sold
-681,348
193
-3,517
senior vp, r&d
Mar 11, 2024
kuriyel ralf
acquired
109,433
86.1
1,271
senior vp, r&d
Mar 08, 2024
hunt anthony
sold
-3,298,630
197
-16,707
chief executive officer
Mar 08, 2024
hunt anthony
acquired
16.55
16.55
1.00
chief executive officer
Mar 07, 2024
bylund james
sold (taxes)
-236,038
195
-1,206
chief operating officer
Mar 07, 2024
hunt anthony
sold (taxes)
-561,129
195
-2,867
chief executive officer
Mar 07, 2024
gebski christine
sold (taxes)
-75,547
195
-386
see remarks
Mar 07, 2024
kuriyel ralf
sold (taxes)
-75,547
195
-386
senior vp, r&d

1–10 of 50

Which funds bought or sold RGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 26, 2024
Fairman Group, LLC
new
-
1,438
1,438
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-11.84
-2,607
820,428
-%
Mar 15, 2024
B. Riley Wealth Advisors, Inc.
reduced
-11.17
1,049
231,582
0.01%
Mar 11, 2024
VANGUARD GROUP INC
added
0.66
110,889,000
913,077,000
0.02%
Mar 04, 2024
CONGRESS ASSET MANAGEMENT CO /MA
added
220
10,003,200
13,808,600
0.11%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
75.8
47,082,600
94,745,100
0.01%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-3.99
997,937
12,654,300
0.05%
Feb 26, 2024
Neo Ivy Capital Management
new
-
164,000
164,000
0.37%
Feb 26, 2024
Virtu Financial LLC
reduced
-60.68
-268,000
215,000
0.02%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-4.53
223,000
3,031,000
0.03%

1–10 of 40

Are Funds Buying or Selling RGEN?

Are funds buying RGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RGEN
No. of Funds

Unveiling Repligen Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
7.2%
4,012,851
SC 13G/A
Feb 13, 2024
vanguard group inc
9.10%
5,078,261
SC 13G/A
Feb 06, 2024
eddleman roy t
4.85%
2,705,689
SC 13G/A
Jan 23, 2024
blackrock inc.
14.1%
7,859,530
SC 13G/A
Feb 15, 2023
eddleman roy t
4.87%
2,705,689
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
9.1%
5,070,657
SC 13G/A
Feb 09, 2023
vanguard group inc
9.37%
5,205,155
SC 13G/A
Jan 23, 2023
blackrock inc.
11.0%
6,123,594
SC 13G/A
Sep 08, 2022
blackrock inc.
10.2%
5,686,997
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.5%
3,042,655
SC 13G

Recent SEC filings of Repligen Corp

View All Filings
Date Filed Form Type Document
Mar 20, 2024
4
Insider Trading
Mar 19, 2024
3
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
8-K
Current Report
Mar 12, 2024
4
Insider Trading
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
4
Insider Trading
Mar 08, 2024
144
Notice of Insider Sale Intent
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading

What is the Fair Value of RGEN?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Repligen Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
40.1B
-3.02% 19.11%
34.4
4.91
-8.12% -17.45%
71.2B
19.5B
2.28% 4.53%
56.69
3.65
4.02% -22.04%
24.6B
3.9B
3.45% 0.50%
55.33
6.38
3.42% 23.09%
21.7B
14.8B
1.75% 11.60%
8.16
1.46
2.12% 209.17%
MID-CAP
10.2B
2.7B
2.92% -30.26%
-16.04
3.83
-4.68% 82.43%
9.7B
12.3B
-3.34% -3.19%
23.21
0.78
-2.44% -22.68%
9.5B
3.5B
2.97% 25.27%
33.57
2.74
4.97% 18.89%
6.9B
4.0B
-2.47% -11.08%
-51.36
1.74
1.10% 85.84%
3.5B
366.4M
0.74% 28.92%
-577.22
9.59
33.86% 89.80%
2.5B
6.6B
-3.84% 3.03%
12.86
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
47.53% -25.51%
-2.23
0.47
7.73% -1066.14%
379.3M
166.7M
5.16% -2.53%
-4.59
2.28
6.67% -456.34%
227.2M
329.5M
-13.41% -54.45%
-16.09
0.69
0.49% 64.22%
43.3M
52.3M
-46.12% -38.06%
-2.31
0.83
17.61% 19.28%
4.5M
3.7M
2.40% 338.46%
-0.37
1.19
5.77% 8.23%

Repligen Corp News

Latest updates
Defense World • 30 hours ago
Defense World • 26 Mar 2024 • 09:47 am
MarketBeat • 25 Mar 2024 • 09:02 pm
Yahoo Finance • 22 Feb 2024 • 08:00 am
Simply Wall St • 13 Feb 2024 • 08:00 am

Repligen Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue10.3%15614115918318720120820618717816314310994.0087.0076.0069.0069.0071.0061.0052.00
Gross Profit-------------60.0054.0051.0044.0039.0038.0040.0034.0028.00
Costs and Expenses14.8%15713614015113814814414614913311510691.0073.0068.0064.0064.0061.0060.0049.0044.00
Operating Expenses-------------91.0073.0068.0064.0064.0061.0060.0049.0044.00
  S&GA Expenses3.7%58.0055.0049.0056.0053.0054.0055.0054.0052.0048.0044.0039.0036.0029.0027.0028.0028.0025.0024.0019.0017.00
  R&D Expenses-2.8%10.0011.0010.0012.0011.0010.0010.0012.009.009.008.008.007.004.004.005.005.005.005.004.003.00
EBITDA Margin-26.8%0.21*0.29*0.52*0.80*1.31*0.31*0.32*0.31*0.30*0.30*0.30*0.28*---------
Interest Expenses323.0%1.000.000.000.000.000.000.000.003.003.003.003.002.003.003.003.003.003.002.002.002.00
Income Taxes356.8%17.00-6.505.007.004.007.0010.0012.006.008.008.004.00-4.923.000.001.001.000.002.002.001.00
Earnings Before Taxes-175.3%-8.7612.0025.0036.0053.0047.0060.0059.0035.0041.0044.0033.0015.0018.0016.0011.004.002.0010.0011.007.00
EBT Margin-46.6%0.10*0.19*0.38*0.62*1.06*0.25*0.25*0.24*0.23*0.23*0.22*0.19*---------
Net Income-240.3%-25.4918.0020.0029.0049.0040.0050.0047.0029.0033.0036.0029.0020.0015.0016.0010.004.002.008.008.006.00
Net Income Margin-62.4%0.07*0.17*0.33*0.53*0.90*0.21*0.20*0.20*0.19*0.20*0.20*0.18*---------
Free Cashflow-41.7%18.0031.0026.003.0041.0030.0020.00-4.0918.0012.0021.002.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets12.3%2,8242,5142,5492,5382,5252,4632,4452,3842,3582,2412,0161,9271,9031,4761,4421,4061,4001,3791,068798775
  Current Assets13.6%1,1119789991,019998953976945932911984926902697687651642622316284276
    Cash Equivalents19.1%751631604517523573597585604621734711717553560539537522218196194
  Inventory-4.3%20221124124523824323921418415613611095.0079.0070.0062.0055.0052.0051.0045.0042.00
  Net PPE2.9%20720220319319117416814812510085.0072.0067.0055.0052.0050.0048.0043.0038.0035.0032.00
  Goodwill13.6%98786987185685685185485986083461861861848213.00468468469470326327
Liabilities62.3%853526578598614627640617608526413371374351342337340334189173159
  Current Liabilities-56.5%15836337440540441142442437534933231331951.0044.0042.0048.0039.00141130130
  Long Term Debt-510--------------------
    LT Debt, Non Current-510--------------------
Shareholder's Equity-0.9%1,9711,9891,9711,9401,9111,8351,8051,7661,7501,7151,6031,5561,5291,1251,1001,0701,0601,045879625616
  Retained Earnings-5.5%43946444642639734930825819416513195.0066.0046.0032.0016.006.002.001.00-7.51-0.68
  Additional Paid-In Capital0.1%1,5691,5671,5611,5451,5471,5411,5341,5291,5721,5601,4751,4681,4611,0881,0821,0741,0681,064893646643
Shares Outstanding0.0%56.0056.0056.0056.0056.0056.0055.0055.0055.0055.0055.0055.00---------
Float---6,932---8,912---10,858---5,712---3,600--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-25.9%29,06539,23134,46811,15461,88241,36745,72123,11349,62022,48337,6519,26214,87121,48916,7359,53017,67421,96517,7899,7885,555
  Share Based Compensation1.4%6,4656,3735,4837,2546,2626,1546,9857,9157,0206,8007,1436,5414,5294,2004,1004,1653,3893,1753,0313,2512,520
Cashflow From Investing-1837.3%-169,905-8,77064,833-9,433-121,308-57,494-26,220-28,214-62,276-132,695-17,201-8,997-158,288-33,580-4,480-5,037-7,111-6,892-187,477-3,828-5,457
Cashflow From Financing34563.6%268,127-778-8,825-9,563-2741,251-2,293-12,021231-122345507298,8381,6763,8131,589-180294,875190,12844.001,044
  Buy Backs----------330------------

RGEN Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Revenue$ 638,764$ 801,536$ 670,534
Costs and operating expenses:   
Cost of product revenue353,922345,830279,280
Research and development42,72243,93634,274
Selling, general and administrative218,113215,829183,866
Contingent consideration(30,569)(28,729)5,865
Total costs and operating expenses584,188576,866503,285
Income from operations54,576224,670167,249
Other income (expenses):   
Investment income24,1356,978176
Interest expense(1,951)(1,162)(11,278)
Loss on extinguishment of debt(12,676)00
Amortization of debt issuance costs(8,075)(1,815)(1,436)
Other income (expenses)8,123(9,531)(1,168)
Other income (expenses), net9,556(5,530)(13,706)
Income before income taxes64,132219,140153,543
Income tax provision22,55533,18125,252
Net income$ 41,577$ 185,959$ 128,291
Earnings per share:   
Basic$ 0.75$ 3.35$ 2.33
Diluted$ 0.74$ 3.24$ 2.24
Weighted average common shares outstanding:   
Basic55,72055,46055,015
Diluted56,37757,45557,264
Net Income (Loss)$ 41,577$ 185,959$ 128,291
Other comprehensive income (loss):   
Foreign currency translation adjustment(3,037)(17,508)(18,971)
Comprehensive income38,540168,451109,320
Products   
Revenue:   
Revenue638,381[1]801,183670,319
Royalty and Other Revenue   
Revenue:   
Revenue$ 383$ 353$ 215
[1]2023 revenue for filtration products includes revenue related to FlexBiosys, Inc. (“FlexBiosys”) from April 17, 2023, as well as Metenova Holding AB (“Metenova”) from October 2, 2023.

RGEN Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 751,323$ 523,458
Marketable securities held to maturity0100,299
Accounts receivable, net of reserves of $2,122 and $1,365 at December 31, 2023 and December 31, 2022, respectively124,161116,247
Inventories, net202,321238,277
Prepaid expenses and other current assets33,23819,837
Total current assets1,111,043998,118
Property, plant and equipment, net207,440190,673
Intangible assets, net400,486353,676
Goodwill987,120855,513
Deferred tax assets1,530840
Operating lease right of use assets115,515125,023
Other noncurrent assets1,277815
Total noncurrent assets1,713,3681,526,540
Total assets2,824,4112,524,658
Current liabilities:  
Accounts payable19,56327,554
Operating lease liability5,6316,957
Current contingent consideration12,98313,950
Accrued liabilities50,53371,120
Convertible Senior Notes due 2024, net69,452284,615
Total current liabilities158,162404,196
Convertible Senior Notes due 2028, net510,1430
Deferred tax liabilities40,46623,000
Noncurrent operating lease liability126,578131,389
Noncurrent contingent consideration14,07051,559
Other noncurrent liabilities3,7893,814
Total noncurrent liabilities695,046209,762
Total liabilities853,208613,958
Commitments and contingencies (Note 13)
Stockholders' equity:  
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding558556
Additional paid-in capital1,569,2271,547,266
Accumulated other comprehensive loss(37,431)(34,394)
Accumulated earnings438,849397,272
Total stockholders' equity1,971,2031,910,700
Total liabilities and stockholders' equity$ 2,824,411$ 2,524,658
RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEwww.repligen.com
 EMPLOYEES2025

Repligen Corp Frequently Asked Questions


What is the ticker symbol for Repligen Corp? What does RGEN stand for in stocks?

RGEN is the stock ticker symbol of Repligen Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repligen Corp (RGEN)?

As of Wed Mar 27 2024, market cap of Repligen Corp is 10.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers. The fair value of Repligen Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repligen Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repligen Corp a good stock to buy?

The fair value guage provides a quick view whether RGEN is over valued or under valued. Whether Repligen Corp is cheap or expensive depends on the assumptions which impact Repligen Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGEN.

What is Repligen Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, RGEN's PE ratio (Price to Earnings) is 247.82 and Price to Sales (PS) ratio is 16.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repligen Corp's stock?

In the past 10 years, Repligen Corp has provided 0.295 (multiply by 100 for percentage) rate of return.